Back to Newsroom
Back to Newsroom

Amarantus BioScience Holdings, Inc. - "Fundamental Milestones Ahead: Up-Listing from Strength"

Thursday, 18 September 2014 01:00 PM

Topic:

New York, NY / ACCESSWIRE / September 18, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Commissiong addresses misinformation he believes is being circulated about Amarantus' proposal to increase the Company's authorized share count. Recognizing that, "the primary concern to [Amarantus'] investors is dilution," Mr. Commissiong outlines the key steps he believes must be taken in order to uplist to a national exchange. Read the full blog post from Mr. Gerald Commissiong on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/fundamental-milestones-ahead-listing-strength/).

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

 

SOURCE: TheChairmansBlog.com 

Topic:
Back to newsroom
Back to Newsroom
Share by: